Connection

Kenneth Tew to Male

This is a "connection" page, showing publications Kenneth Tew has written about Male.
Connection Strength

0.269
  1. S-Glutathionylated Serine Proteinase Inhibitors as Biomarkers for Radiation Exposure in Prostate Cancer Patients. Sci Rep. 2019 09 24; 9(1):13792.
    View in: PubMed
    Score: 0.036
  2. Ablation of the ATP-binding cassette transporter, Abca2 modifies response to estrogen-based therapies. Biomed Pharmacother. 2012 Sep; 66(6):403-8.
    View in: PubMed
    Score: 0.022
  3. ABCA2 transporter deficiency reduces incidence of TRAMP prostate tumor metastasis and cellular chemotactic migration. Cancer Lett. 2011 Jan 28; 300(2):154-61.
    View in: PubMed
    Score: 0.019
  4. "Skittish" Abca2 knockout mice display tremor, hyperactivity, and abnormal myelin ultrastructure in the central nervous system. Mol Cell Biol. 2007 Jan; 27(1):44-53.
    View in: PubMed
    Score: 0.015
  5. Evaluation of lipophilins as determinants of tumor cell response to estramustine. J Pharmacol Exp Ther. 2005 Dec; 315(3):1158-62.
    View in: PubMed
    Score: 0.014
  6. Identification of a novel first exon of the human ABCA2 transporter gene encoding a unique N-terminus. Biochim Biophys Acta. 2004 Apr 16; 1678(1):22-32.
    View in: PubMed
    Score: 0.012
  7. Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. J Clin Invest. 2021 08 16; 131(16).
    View in: PubMed
    Score: 0.010
  8. A seleno-hormetine protects bone marrow hematopoietic cells against ionizing radiation-induced toxicities. PLoS One. 2019; 14(4):e0205626.
    View in: PubMed
    Score: 0.009
  9. Impact of dietary supplement of Crassostrea gigas extract (JCOE) on glutathione levels and glutathione S-transferase activity in rat tissues. In Vivo. 1998 May-Jun; 12(3):299-303.
    View in: PubMed
    Score: 0.008
  10. The antioxidant effects of Crassostrea gigas extract (JCOE) in human volunteers. In Vivo. 1998 May-Jun; 12(3):305-9.
    View in: PubMed
    Score: 0.008
  11. Interaction of estramustine with tubulin isotypes. Biochemistry. 1997 Jan 28; 36(4):871-8.
    View in: PubMed
    Score: 0.008
  12. Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells. Mol Pharmacol. 1994 Nov; 46(5):866-72.
    View in: PubMed
    Score: 0.006
  13. Peroxiredoxin VI oxidation in cerebrospinal fluid correlates with traumatic brain injury outcome. Free Radic Biol Med. 2014 Jul; 72:210-21.
    View in: PubMed
    Score: 0.006
  14. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 1992 Aug 15; 52(16):4433-40.
    View in: PubMed
    Score: 0.006
  15. Contribution of patient history to the glutathione S-transferase activity of human lung, breast and colon tissue. Carcinogenesis. 1991 Oct; 12(10):1957-61.
    View in: PubMed
    Score: 0.005
  16. Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype. Br J Cancer. 1991 Aug; 64(2):267-73.
    View in: PubMed
    Score: 0.005
  17. Cocaine-induced adaptations in cellular redox balance contributes to enduring behavioral plasticity. Neuropsychopharmacology. 2011 Nov; 36(12):2551-60.
    View in: PubMed
    Score: 0.005
  18. Glutathione S-transferases in normal and malignant human colon tissue. Biochim Biophys Acta. 1991 Apr 15; 1096(3):209-16.
    View in: PubMed
    Score: 0.005
  19. The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells. Eur J Cell Biol. 1991 Apr; 54(2):268-76.
    View in: PubMed
    Score: 0.005
  20. Mechanism based chemotherapy for prostate cancer. Cancer Surv. 1991; 11:239-54.
    View in: PubMed
    Score: 0.005
  21. Characterization of glutathione S-transferase expression in lymphocytes from chronic lymphocytic leukemia patients. Cancer Res. 1990 Jun 15; 50(12):3562-8.
    View in: PubMed
    Score: 0.005
  22. Intracellular effects of estramustine (Estracyt/Emcyt). Prog Clin Biol Res. 1989; 303:169-75.
    View in: PubMed
    Score: 0.004
  23. Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity. Biomed Pharmacother. 2009 Feb; 63(2):79-85.
    View in: PubMed
    Score: 0.004
  24. Glutathione S-transferases in human prostate. Biochim Biophys Acta. 1987 Oct 08; 926(1):8-15.
    View in: PubMed
    Score: 0.004
  25. Hormone-independent, non-alkylating mechanism of cytotoxicity for estramustine. Urol Res. 1987; 15(3):155-60.
    View in: PubMed
    Score: 0.004
  26. Relationship of glutathione depletion and inhibition of glutathione-S-transferase activity to the antimitotic properties of estramustine. Cancer Treat Rep. 1986 Jun; 70(6):715-20.
    View in: PubMed
    Score: 0.004
  27. Dansylated estramustine, a fluorescent probe for studies of estramustine uptake and identification of intracellular targets. Proc Natl Acad Sci U S A. 1985 Dec; 82(24):8483-7.
    View in: PubMed
    Score: 0.003
  28. Antimicrotubule effects of estramustine, an antiprostatic tumor drug. Cancer Res. 1985 Aug; 45(8):3891-7.
    View in: PubMed
    Score: 0.003
  29. Biochemical and cytotoxic properties of the isomeric forms of N,N'-bis[N-2-chloroethyl)-N-nitrosocarbamoyl] cystamine. Biochem Pharmacol. 1984 Aug 15; 33(16):2575-80.
    View in: PubMed
    Score: 0.003
  30. Cytotoxic properties of estramustine unrelated to alkylating and steroid constituents. Urology. 1984 Jun; 23(6 Suppl):28-33.
    View in: PubMed
    Score: 0.003
  31. The mechanism of action of estramustine. Semin Oncol. 1983 Sep; 10(3 Suppl 3):21-6.
    View in: PubMed
    Score: 0.003
  32. Cyclophosphamide and cis-dichlorodiammine platinum (11). Nonempiric scheduling to spare dose-limiting tissues in the rat. Cancer Chemother Pharmacol. 1980; 4(2):103-9.
    View in: PubMed
    Score: 0.002
  33. Estramustine resistance correlates with tau over-expression in human prostatic carcinoma cells. Int J Cancer. 1998 Aug 12; 77(4):626-31.
    View in: PubMed
    Score: 0.002
  34. Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression. Biochem Pharmacol. 1998 Feb 01; 55(3):325-31.
    View in: PubMed
    Score: 0.002
  35. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res. 1996 Jun 01; 56(11):2584-9.
    View in: PubMed
    Score: 0.002
  36. Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother Pharmacol. 1996; 37(4):363-70.
    View in: PubMed
    Score: 0.002
  37. Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. Hematol Oncol Clin North Am. 1995 Apr; 9(2):383-96.
    View in: PubMed
    Score: 0.002
  38. Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J Pharmacol Exp Ther. 1994 Sep; 270(3):1186-91.
    View in: PubMed
    Score: 0.002
  39. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992 Nov; 10(11):1754-61.
    View in: PubMed
    Score: 0.001
  40. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res. 1991 Nov 15; 51(22):6059-65.
    View in: PubMed
    Score: 0.001
  41. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J Cell Biol. 1988 Dec; 107(6 Pt 2):2647-56.
    View in: PubMed
    Score: 0.001
  42. Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine. Anticancer Res. 1987 Nov-Dec; 7(6):1165-71.
    View in: PubMed
    Score: 0.001
  43. Mechanism of action of 2-haloethylnitrosoureas on deoxyribonucleic acid. Pathways of aqueous decomposition and pharmacological characteristics of new anticancer disulfide-linked nitrosoureas. Biochem Pharmacol. 1985 Apr 01; 34(7):1015-24.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.